Managing Partner, SV Health Investors
Former COO, Boston Scientific
Former President VC, Boston Scientific

Former President, International, Boston Scientific

Paul joined SV in 2009 as a Venture Partner and in 2011 was made a Partner. Paul was promoted to Managing Partner & COO in 2014 and heads our medical device investments.

Prior to SV, Paul built and ran medical device businesses for 29 years before joining SV Health Investors. Most recently he was Chief Operating Officer at Boston Scientific (BSC), an $8 billion medical device leader. During his 15 years at BSC, Paul served as Chief Operating Officer; Group President, Cardiovascular; President, Cardiology; Group President, Endosurgery; and President, International.


During his tenure, the company grew revenue over 20 times. Paul integrated two dozen acquisitions and led extensive product development, manufacturing and worldwide commercial organizations. Previously, Paul held marketing and general management positions at CR Bard and various marketing roles at Kendall (Medtronic).


Outside of SV, Paul serves as Chairman of the Medical Device Manufacturing Association and as Vice Chairman of the Innovation Advisory Board for the Partners Health System. Paul also served on the board of Advamed for 10 years and is a routine speaker at industry meetings.


Academic Credentials
BA, Psychology, Fairfield University; MBA, Boston College



VP, Venture Capital, Medtronic

Frm VP, Director Venture Capital, Covidien

Frm VP, Director Venture Capital, Stryker

As Vice President of Venture Capital at Medtronic, Dave works closely with Medtronic’s leadership to complete new venture capital investments in areas of strategic interest and socialize key developments at existing portfolio companies. Dave has completed a large number of investments over the years and serves or has served as a Director or Observer on approximately 20 Boards including superDimension, Idev, Medina, and Entellus.

Prior to Medtronic, Dave served in similar roles at Covidien and Stryker. While at Covidien, he also led a process to prioritize white space opportunities for the company. Earlier in his career, as a healthcare-focused strategy consultant, Dave supported clients on decisions regarding acquisition opportunities and internal R&D prioritization across the medical device, diagnostic and biopharmaceutical industries. He received his Ph.D. in molecular biology from the University of British Columbia, and an MBA from Yale University, and completed post-doctoral fellowships at the Mount Sinai School of Medicine.



Co-Founder, St. Jude Medical VP, Director Venture Capital, Covidien

Frm VP, Director Venture Capital, Stryker

Peter is a successful serial health-tech entrepreneur having been the founder of CliniCom Inc, a leader in the electronic medical record industry eventually acquired by McKesson; a Co-Founder of St. Jude Medical and former sales and marketing executive at Medtronic, both global leaders in the medical device industry.  Peter started OncoGenesis with a passion for expanding cervical cancer screening access and improving early detection of cervical disease.



CEO, Atomwise

Abraham Heifets is cofounder and CEO of Atomwise. He was a Massey Fellow at the University of Toronto and the Ontario Brain Institute, where his doctoral work used machine learning to plan organic syntheses, a long-standing challenge in chemistry. Previously, Abraham researched compilers for high-performance data processing at IBM's T.J. Watson Research Center and helped build the AI system of the world-champion robotic soccer team at Cornell University. He was a Time Person of the Year in 2006.  Heifets' research on AI-enhanced drug discovery was also featured in the July 2019 Moonshot issue of Newsweek. 


Founder, Rejuvenan

Frm Chairman, Oxford Health
GP/Founder of 7 Venture Funds

Fred Nazem, entrepreneur and philanthropist, has founded or financed several multi-billion dollar corporations. Known also as a turnaround specialist, he led the reorganization and successful reversal of Oxford Health Plans which was later sold to United Healthcare for $5 billion. He is a corporate architect, biochemist, high tech innovator, investor and leader.

Fred Nazem began his career in the financial industry in the late 1970's. As founder of Nazem and Company, he managed seven private venture capital funds and a joint venture in partnership with Banque National De Paris of France. In the four decades since its founding, Mr. Nazem has started, financed or guided more than three hundred cutting edge enterprises. With an ever-expanding width of experience, he has defined new fields and ideas in finance, high technology and healthcare. Several of the companies founded by Mr. Nazem have become multi-billion dollar enterprises. A most recent venture is Rejuvenan Global Health, a highly digital, membership based healthcare delivery system which provides its members with the knowledge and tools they need to own and manage their health and the health of their families.


Mr. Nazem is also well-known for his role as a turnaround specialist. In 1997, as Chairman of Oxford Health Plans, he led the reorganization and successful reversal as the company experienced operational and financial difficulties. Oxford was later sold to the United Health Group for $5 billion. As director of one of America's most prominent family fortunes, Mr. Nazem orchestrated a dramatic turnaround from near bankruptcy to a ranking on the Forbes 400 list for wealthiest people of the world. He has namaged private wealth for four decades and currently is Managing Partner of Hedgeworth Capital, a private fund founded in 2003.


Alongside his business ventures, Mr. Nazem devotes much of his time and energy to important philanthropic concerns. Primarily working through the Nazem Family Foundation, he has supported many civic, educational and healthcare-related cases. He currently serves on the Science and Technology Advisory Board of Columbia Presbyterian Medical Center. Furthermore, he is a member of the New York Society of Security Analysts and the Economic Club of New York. Mr. Nazem is a recipient of the Ellis Island Medal of Honor, an award granted to American citizens of diverse origins for their outstanding contributions to the United States.


Fred Nazem received a Bachelor of Science degree in biochemistry from Ohio State University, a Master of Science in physical chemistry from University of Cincinnati and an MBA in finance from Columbia University. He also did doctoral work in quantum physics at Washington University. Mr. Nazem worked as a chemist at Keebler and Company, and Matheson Coleman and Bell before he ventured to Wall Street. He served as a securities analyst and Assistant Vice President at Irving Trust Company (now Bank of New York) before founding his own venture capital firm.


Co-founder/Managing Partner, DigitalDx Ventures

Michele Colucci, Co-founder/Managing Partner, is a lawyer, investor, serial entrepreneur, and philanthropist. She has authored five patents in the technology space and founded companies in the legal, technology, retail, and entertainment spaces. Michele’s extensive experience operating in highly regulated verticals has focused on issues from management to legal (employment, corporate, International, litigation, torts, negotiations, business strategy, and marketing). Her most recent company focused on the application of big data and artificial intelligence in legal technology. She has worked at law firms including Hughes Hubbard & Reed, run her own media production company, owned and operated a chain of retail stores in the political space, run a political fundraising venue, and founded a legal technology company. 
Currently, Michele serves on public and private Boards of Directors at Global Indemnity Group, Nephrosant, Optina Diagnostics, Prime Genomics, and Trayt. She is also an Advisor to eHealth Analytics (a digital health startup) and Quantellia (a platform powering decision-based analytics through artificial intelligence). She is a Huffington Postblogger on female entrepreneurship and an award-winning expert on E-Local. She has served as a regular guest lecturer and mentor at Stanford University’s School of Engineering focused on Global Marketing and Entrepreneurship and has lectured at USC’s Gould School of Law. 
In 2017 Michele was named by the Nobel Laureate Foundation as a West Coast Ambassador for her ongoing work in concert the Nobel Laureate Foundation to expand their global footprint and aid young scientists— selected from around the world to attend their summer program—to connect, learn, and interact with Nobel Laureates in their field of study. She has served on nonprofit boards including NOFAS (National Organization for Fetal Alcohol Syndrome), Hope After Divorce, and City Hearts.

The Silicon Valley Business Journal honored Michele as a ‘Silicon Valley Woman of Influence.’ She was featured in a cover article of the American Bar Journal as a ‘Leading Woman in Legal Technology’ and named a ‘Person to Watch’ by Silicon Valley’s Gentry Magazine. Michele’s accomplishments have been featured in a variety of media including NBC, Inc. Magazine, Redbook, and the San Jose Mercury News.

Michele earned her Bachelor’s degrees in English and Philosophy and J.D. from Georgetown University. She earned a Master’s in Fine Arts from the American Film Institute. She speaks three languages, and lives in Silicon Valley with her four children. 



"The Healthcare IT Guy"
Former CTO of CTS, Cardinal Health

CEO, Citus Health

Shahid Shah is an internationally recognized and influential healthcare IT thought leader and multiple patent awardee who is known as “The Healthcare IT Guy'' across the Internet. He is a serial entrepreneur and technology strategy advisor to many federal agencies and winner of Federal Computer Week’s coveted “Fed 100″ award given to IT experts that have made a big impact on the US government. 


Shahid has architected and built multiple clinical solutions over his almost 30-year career. He helped design and deploy electronic health record solutions across thousands of sites for the American Red Cross. He is a serial entrepreneur who has cofounded and exited two Electronic Health Records companies and co-founded and is currently scaling a third EHR company focused on digital front door, patient engagement, and remote patient monitoring. He’s designed large professional collaboration sites and, as an ex-CTO for CardinalHealth’s CTS medical devices division (now part of Becton Dickinson), he helped design advanced clinical interfaces for hospital based medical devices. Shahid also has served as a senior technology strategy advisor to NIH’s and TATRC’s SBIR/STTR program helping startups commercialize their healthcare applications.


For the past 30 years Shahid has held the positions of CEO, CTO, VP of Technology, Chief Software Architect, or Enterprise Architect at large enterprises. His technology expertise includes AI, machine learning, conversational user experiences, service-oriented and event modeling architectures, and trust networks backed by immutable databases and blockchain. His healthcare focus starts with an emphasis on e-health, EMRs, HL7/FHIR-based data integration, and legacy modernization but his passions also include innovation evaluation, tech due diligence, real world evidence collection, and clinical trial design.


These days, as publisher of Medigy.com, he’s focused on trying to figure out how transparent, crowd-sourced, and credentialed peer reviews can separate real healthcare innovations from marginal or fake ones. Medigy.com is an effort to bring some of the transparency we have seen in online product reviews to medical device, digital health, and life sciences innovation. At its best, Medigy can help identify innovations worth investing in…or innovations that are not likely to produce the outcomes we desire.